TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26244306

Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Number of subjects: 422

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Tenofovir gel (with vaginal concentrations of 10,000 ng/mL or more)
Number of subjects: 422

Group type: COMPARATOR
Intervention: No detectable vaginal tenofovir
Number of subjects: 422
Study: 23578015

Group type: EXPERIMENTAL
Intervention: 1.2 mg/kg/day atomoxetine for 20 weeks
Number of subjects: 88
Study: 21320923

Group type: EXPERIMENTAL
Intervention: Atazanavir plus ritonavir
Number of subjects: 928

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 928
Study: 18812431

Group type: EXPERIMENTAL
Intervention: Cortical stimulation (CS) combined with rehabilitation for 6 weeks, delivered during therapy.
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group receiving the same therapy without device implantation or stimulation.
Number of subjects: 174
Study: 16904298

Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs (haloperidol, risperidone, olanzapine, quetiapine)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study: 15051771

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (RT)
Number of subjects: 99
Study: 12215593

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK) treatment
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 9578190

Group type: EXPERIMENTAL
Intervention: Oral theophylline 10 mg kg(‐1) day(‐1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 7713093

Group type: EXPERIMENTAL
Intervention: Coumarin anticoagulation (Group I)
Number of subjects: 200

Group type: COMPARATOR
Intervention: No oral anticoagulation (Group II)
Number of subjects: 200
Study: 1369851

Group type: EXPERIMENTAL
Intervention: McIntosh hemiarthroplasty of the knee
Number of subjects: 35
Study: 360120

Group type: EXPERIMENTAL
Intervention: Cefazolin (8-hour, 3-dose regimen)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 97
Study: 31159776

Group type: EXPERIMENTAL
Intervention: S&G exercise intervention (combining supervised exercise with gamification and social incentives via WeChat)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: S&G exercise intervention
Number of subjects: 420

Group type: COMPARATOR
Intervention: Supervised exercise (SE)
Number of subjects: 420
Study: 28296334

Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg single dose
Number of subjects: 24
Study: 25220215

Group type: EXPERIMENTAL
Intervention: 40 mg methylphenidate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 23298335

Group type: EXPERIMENTAL
Intervention: Dietary phylloquinone intake (upper tertile)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Dietary phylloquinone intake (lowest tertile)
Number of subjects: 510
Study: 21672543

Group type: EXPERIMENTAL
Intervention: Cues to low cortisol in male faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: High testosterone levels
Number of subjects: 0
Study: 18049097

Group type: EXPERIMENTAL
Intervention: 99mTc-DTPA aerosol inhalation scintigraphy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pulmonary function tests (PFT)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 28

Group type: COMPARATOR
Intervention: 99mTc-DTPA clearance
Number of subjects: 28
Study: 16865577

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen/progestin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen/progestin and Placebo
Number of subjects: 31
Study: 12771325

Group type: EXPERIMENTAL
Intervention: Lignan intake (173 microg/d for men, 151 microg/d for women)
Number of subjects: 2852
Study: 11128344

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 150 mg/daily
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 9097868

Group type: EXPERIMENTAL
Intervention: High-dose naltrexone (100 mg bid) followed by 200 mg bid during open-label period
Number of subjects: 0
Study: 8460346

Group type: EXPERIMENTAL
Intervention: alpha‐streptococci
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 3539851

Group type: EXPERIMENTAL
Intervention: Prophylactic granulocyte transfusions (PG)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Prophylactic systemic antibiotics (PSA)
Number of subjects: 112
Study: 30541563

Group type: EXPERIMENTAL
Intervention: Physical Activity Loyalty Scheme (PAL) intervention involving rewards for increasing physical activity; participants earned points for minutes of activity that could be redeemed for rewards, complemented by evidence-based behaviour change techniques.
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: Physical Activity Loyalty Scheme (PAL) intervention
Number of subjects: 853

Group type: COMPARATOR
Intervention: Control group (wait-list controlled)
Number of subjects: 853
Study: 26598744

Group type: EXPERIMENTAL
Intervention: Lapatinib + Trastuzumab (L+T)
Number of subjects: 8381

Group type: EXPERIMENTAL
Intervention: Trastuzumab followed by Lapatinib (T->L)
Number of subjects: 8381

Group type: COMPARATOR
Intervention: Trastuzumab (T)
Number of subjects: 8381
Study: 23887684

Group type: EXPERIMENTAL
Intervention: Oral clonidine premedication followed by intraoperative saline infusion (group A)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo premedication followed by dexmedetomidine infusion (group B)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Both groups (clonidine and dexmedetomidine)
Number of subjects: 74
Study: 23948783

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Yokukansan
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 90
Study: 21244668

Group type: EXPERIMENTAL
Intervention: Structured Education Pulmonary Rehabilitation Programme (SEPRP) delivered by practice nurses and physiotherapists
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 320
Study: 18438247

Group type: EXPERIMENTAL
Intervention: VertiMax training group
Number of subjects: 64

Group type: COMPARATOR
Intervention: Training control group
Number of subjects: 64
Study: 17154731

Group type: EXPERIMENTAL
Intervention: toddler-parent psychotherapy (DI)
Number of subjects: 130

Group type: COMPARATOR
Intervention: control group (DC)
Number of subjects: 130

Group type: COMPARATOR
Intervention: nondepressed comparison group (NC)
Number of subjects: 130
Study: 12687826

Group type: EXPERIMENTAL
Intervention: Atrial lead positions in physiological pacing (RA free wall, RA appendage, near coronary sinus ostium, dual site RA pacing)
Number of subjects: 0
Study: 11017811

Group type: EXPERIMENTAL
Intervention: Prednisolone, 60 mg/day for 2 weeks
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 9251115

Group type: EXPERIMENTAL
Intervention: Hepatic intra-arterial (HIA) chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic chemotherapy
Number of subjects: 0
Study: 1609034

Group type: EXPERIMENTAL
Intervention: Haloperidol treatment with 50% dose decrease
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3303753

Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of MTX and 5-FU (therapy arm A)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Systematic treatment with CMFV combination (therapy arm B)
Number of subjects: 43
Study: 29544607

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 7213

Group type: COMPARATOR
Intervention: UFH
Number of subjects: 7213

Group type: COMPARATOR
Intervention: UFH with GPI
Number of subjects: 7213
Study: 27169702

Group type: EXPERIMENTAL
Intervention: EORTC QLQ‐C30 pain scale (pain intensity and pain interference)
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: EORTC QLQ‐C30
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: EORTC QLQ‐C30 pain intensity item
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: EORTC QLQ‐C30 pain scale
Number of subjects: 1447

Group type: EXPERIMENTAL
Intervention: Pain experience and pain burden
Number of subjects: 1447
Study: 25007368

Group type: EXPERIMENTAL
Intervention: Luliconazole cream 1%
Number of subjects: 321

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 321
Study: 22698293

Group type: EXPERIMENTAL
Intervention: Small titanium plates
Number of subjects: 127

Group type: COMPARATOR
Intervention: Large titanium plates
Number of subjects: 127
Study: 20332720

Group type: EXPERIMENTAL
Intervention: Alcohol injection to the motor branches of tibial nerve
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Phenol injection to the motor branches of tibial nerve
Number of subjects: 20
Study: 17972162

Group type: EXPERIMENTAL
Intervention: Bare Metal Stent (BMS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sirolimus-Eluting Stent (SES)
Number of subjects: 20
Study: 16607468

Group type: EXPERIMENTAL
Intervention: Pramipexole (1.5 to 4.5 mg/day)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sertraline (50 mg/day)
Number of subjects: 67
Study: 14615578

Group type: EXPERIMENTAL
Intervention: Antidepressant (nefazodone)
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Combination of antidepressant and psychotherapy
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Psychotherapy alone
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Combination of psychotherapy and pharmacotherapy
Number of subjects: 681
Study: 10524470

Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone given every 12 hours
Number of subjects: 57

Group type: COMPARATOR
Intervention: Immediate-release oxycodone given four times daily
Number of subjects: 57
Study: 7676793

Group type: EXPERIMENTAL
Intervention: 24G Sprotte needle
Number of subjects: 200

Group type: COMPARATOR
Intervention: 27G Quincke needle
Number of subjects: 200
Study: 1975246

Group type: EXPERIMENTAL
Intervention: Alpha-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blockers with concurrent alpha-blocker
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (enalapril)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7009255

Group type: EXPERIMENTAL
Intervention: Clomipramine (25 mg daily)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 31411768

Group type: EXPERIMENTAL
Intervention: Abaloparatide 80 μg daily (subcutaneous injection) for 18 months followed by alendronate 70 mg once weekly for up to 24 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo followed by alendronate 70 mg once weekly for up to 24 months
Number of subjects: 0
Study: 28719669

Group type: EXPERIMENTAL
Intervention: Nutritional supplement (SUPP; n = 25; 30 g whey protein, 2.5 g creatine, 500 IU vitamin D, 400 mg calcium, 1500 mg n‐3 PUFA)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Nutritional supplement (SUPP + EX)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (CON; n = 24; 22 g of maltodextrin)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (CON + EX)
Number of subjects: 49
Study: 26505596

Group type: COMPARATOR
Intervention: LABA + ICS
Number of subjects: 1070

Group type: EXPERIMENTAL
Intervention: Tiotropium + ICS
Number of subjects: 1070
Study: 23474882

Group type: EXPERIMENTAL
Intervention: Text messaging-based education and behavioral support for 14 days
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (not receiving text-message support)
Number of subjects: 43
Study: 21536612

Group type: EXPERIMENTAL
Intervention: First exposure to high altitude (3450 m)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Second exposure to high altitude (3450 m)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Comparison of AMS incidence between adults and children
Number of subjects: 56

Group type: COMPARATOR
Intervention: Intraindividual reproducibility of AMS
Number of subjects: 56

Group type: COMPARATOR
Intervention: AMS predictive value based on history
Number of subjects: 56
Study: 18973934

Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 4
Study: 16400043

Group type: EXPERIMENTAL
Intervention: Reduced portion size (25% decrease)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Reduced energy density (25% decrease)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined reduction in portion size and energy density
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (standard portion size and energy density)
Number of subjects: 24
Study: 15252005

Group type: EXPERIMENTAL
Intervention: League tables
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control charts
Number of subjects: 122
Study: 11760164

Group type: EXPERIMENTAL
Intervention: Clinafloxacin (200 mg/d)
Number of subjects: 527

Group type: COMPARATOR
Intervention: Ceftriaxone (2 g/d; with or without erythromycin)
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Clinafloxacin
Number of subjects: 527

Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 527
Study: 9408806

Group type: COMPARATOR
Intervention: Paroxetine (20 mg/day) plus placebo for 4 weeks
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day) plus pindolol (7.5 mg/day) for 1 week and placebo for 3 weeks
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day) plus pindolol (7.5 mg/day) for 4 weeks
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day) plus metoprolol (50 mg/day)
Number of subjects: 63
Study: 8280499

Group type: EXPERIMENTAL
Intervention: Breast self-examination (BSE) education programme
Number of subjects: 193000

Group type: COMPARATOR
Intervention: Control group (no BSE education)
Number of subjects: 193000
Study: 3696921

Group type: EXPERIMENTAL
Intervention: Insoluble task
Number of subjects: 66

Group type: COMPARATOR
Intervention: Solvable task
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Facial Action Coding System
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Corrugator responses
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Corrugator response activity
Number of subjects: 66
Study: 31570114

Group type: EXPERIMENTAL
Intervention: Intervention promoting fruit and vegetable consumption
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 225
Study: 29452599

Group type: EXPERIMENTAL
Intervention: 2 to 6 weeks' pre-operative exercise programme
Number of subjects: 20

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 20
Study: 27310522

Group type: EXPERIMENTAL
Intervention: Volume-stable collagen matrix (VCMX)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Autogenous subepithelial connective tissue graft (SCTG)
Number of subjects: 20
Study: 23772856

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM), 750 mg, two doses, 1 week apart (Group A)
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM), 750 mg, two doses, 1 week apart (Group C)
Number of subjects: 1011

Group type: COMPARATOR
Intervention: Oral iron, 325 mg, 3 times a day for 14 days (Group B)
Number of subjects: 1011

Group type: COMPARATOR
Intervention: Standard-of-care IV iron (Group D)
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 1011

Group type: COMPARATOR
Intervention: Standard-of-care IV iron
Number of subjects: 1011
Study: 22962287

Group type: EXPERIMENTAL
Intervention: Intense intermittent exercise (24 bouts of 1 min cycling at 316 ± 19 W, 3 times per week for 4 weeks)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Moderate-intensity exercise
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 4 weeks of high-intensity training
Number of subjects: 9
Study: 20705778

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (UG) with 1.5% mepivacaine, starting dose 13 mL for median nerve
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neurostimulation (NS) with 1.5% mepivacaine, starting dose 11 mL for ulnar nerve
Number of subjects: 0
Study: 19117154

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% + sufentanil 0.75 microg mL‐1 (Group-I)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ropivacaine 0.2% (Group-II)
Number of subjects: 50
Study: 16600560

Group type: EXPERIMENTAL
Intervention: Short-term pre-operative radiotherapy
Number of subjects: 0
Study: 12544181

Group type: EXPERIMENTAL
Intervention: 0.60 mg/kg methylphenidate
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.15 mg/kg methylphenidate
Number of subjects: 24
Study: 10573560

Group type: EXPERIMENTAL
Intervention: High vegetable diet
Number of subjects: 56
Study: 8935018

Group type: EXPERIMENTAL
Intervention: 30 mg ketorolac
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 2% mepivicaine with 1:20 K levonordefrin
Number of subjects: 52

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 52
Study: 1927953

Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 6614894

Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 157

Group type: COMPARATOR
Intervention: Amikacin
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Tobramycin (after excluding high levels)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Amikacin (after excluding high levels)
Number of subjects: 157
Study: 31944576

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) for at least 3 minutes
Number of subjects: 17

Group type: COMPARATOR
Intervention: Immediate cord clamping (historical control)
Number of subjects: 17
Study: 31083015

Group type: EXPERIMENTAL
Intervention: A-mode ultrasound (US)
Number of subjects: 43
Study: 29703242

Group type: EXPERIMENTAL
Intervention: eHealth program
Number of subjects: 110

Group type: COMPARATOR
Intervention: usual care supervised health program
Number of subjects: 110
Study: 27039381

Group type: EXPERIMENTAL
Intervention: Progressive strength training during hospitalization and after discharge (home-based)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study: 23943850

Group type: EXPERIMENTAL
Intervention: Levamisole hydrochloride (150 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No adjuvant to antimalarial treatment (Control)
Number of subjects: 56
Study: 22997691

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (unchanged or deteriorated)
Number of subjects: 34
Study: 20729270

Group type: EXPERIMENTAL
Intervention: DESMOND intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DESMOND intervention (using 'real world' costs)
Number of subjects: 0
Study: 17701094

Group type: EXPERIMENTAL
Intervention: Low fluoride dose (≤20 mg fluoride equivalents)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fluoride treatment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fluoride treatment with daily dose >20 mg fluoride equivalents
Number of subjects: 25
Study: 15899105

Group type: EXPERIMENTAL
Intervention: Post-marketing surveillance studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-marketing pharmacovigilance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-marketing surveillance (PMS) studies
Number of subjects: 0
Study: 12803658

Group type: EXPERIMENTAL
Intervention: Embolization with controlled detachable coils
Number of subjects: 0

Group type: COMPARATOR
Intervention: Early coiling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical treatment (clipping)
Number of subjects: 0
Study: 9723299

Group type: EXPERIMENTAL
Intervention: Neoral
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prograf
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sandimmune
Number of subjects: 0
Study: 7912947

Group type: EXPERIMENTAL
Intervention: Balanced anaesthesia with fentanyl (4 micrograms kg‐1 bolus followed by 1 microgram kg‐1 h‐1 infusion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoflurane (1.1% end‐tidal)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Balanced anaesthesia with thiopentone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoflurane with thiopentone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Balanced anaesthesia with fentanyl
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 30
Study: 2598976

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg i.v.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29153299

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 86
Study: 27879582

Group type: EXPERIMENTAL
Intervention: Carbon dioxide expanders
Number of subjects: 150

Group type: COMPARATOR
Intervention: Saline expanders
Number of subjects: 150
Study: 24336012

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 22397392

Group type: EXPERIMENTAL
Intervention: Total dairy intake
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Soured milk products
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Yoghurt
Number of subjects: 554

Group type: COMPARATOR
Intervention: Cheese
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Lactose
Number of subjects: 554

Group type: COMPARATOR
Intervention: Calcium
Number of subjects: 554
Study: 20147814

Group type: EXPERIMENTAL
Intervention: Serum CTX test performed preoperatively in 54 patients taking oral bisphosphonates (BPs)
Number of subjects: 163

Group type: COMPARATOR
Intervention: No CTX test performed in 109 patients taking oral BPs (control group)
Number of subjects: 163
Study: 18214726

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 998

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 998
Study: 15669886

Group type: EXPERIMENTAL
Intervention: Paroxetine CR (25-75 mg/day)
Number of subjects: 889

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 889